Phase II basket study of olaparib and durvalumab: Biomarker analysis in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) and relapsed small-cell lung cancer (SCLC) patients

被引：0

作者：

Angell, Helen ^{[1
]}

Ros, Vidalba Rocher ^{[1
]}

Standifer, Nathan ^{[2
]}

Lai, Zhongwu ^{[1
]}

Gresty, Christopher ^{[1
]}

Delord, Jean-Pierre ^{[3
]}

De Jonge, Maja ^{[4
]}

Postel-Vinay, Sophie ^{[5
]}

Italiano, Antoine ^{[6
]}

Krebs, Matthew G. ^{[7
,8
]}

Kaufman, Bella ^{[9
]}

Park, Yeon Hee ^{[10
]}

Domchek, Susan ^{[11
]}

Herbolsheimer, Pia ^{[12
]}

Hodgson, Darren ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] MedImmune, Mountain View, CA USA

[3] Inst Claudius Regaud Oncopole, Toulouse, France

[4] Erasmus MC Canc Inst, Rotterdam, Netherlands

[5] Gustave Roussy Canc Campus, Villejuif, France

[6] Inst Bergonie, Bordeaux, France

[7] Univ Manchester, Manchester, Lancs, England

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

[9] Sheba Med Ctr, Ramat Gan, Israel

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[11] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[12] AstraZeneca, Gaithersburg, MD USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P257

引用

页数：2

共 50 条

[21] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Balmana, Judith
Fasching, Peter A.
Couch, Fergus J.
Delaloge, Suzette
Labidi-Galy, Intidhar
O'Shaughnessy, Joyce
Park, Yeon Hee
Eisen, Andrea F.
You, Benoit
Bourgeois, Hughes
Goncalves, Anthony
Kemp, Zoe
Swampillai, Angela
Jankowski, Tomasz
Sohn, Joo Hyuk
Poddubskaya, Elena
Mukhametshina, Guzel
Aksoy, Sercan
Timcheva, Constanta V.
Park-Simon, Tjoung-Won
Anton-Torres, Antonio
John, Ellie
Baria, Katherine
Gibson, Isabel
Gelmon, Karen A.
Koynova, Tatyana
Popov, Vasil
Timcheva, Constanta
Tomova, Antoaneta
Eisen, Andrea
Gelmon, Karen
Lemieux, Julie
Augereau, Paule
Bazan, Fernando
Becuwe, Celia
Bourgeois, Hugues
Chakiba, Camille
Chehimi, Mohamad
Cheneau, Caroline
Dalenc, Florence
de Guillebon, Eleonore
de la Motte Rouge, Thibault
Frenel, Jean-Sebastien
Goncalves, Anthony
Grenier, Julien
Hardy-Bessard, Anne Claire
Lamy, Regine
Levy, Christelle
Lortholary, Alain
Mailliez, Audrey
BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 237 - 248
[22] Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
Laura M. Spring
Hyo Han
Minetta C. Liu
Erika Hamilton
Hanna Irie
Cesar A. Santa-Maria
James Reeves
Peng Pan
Ming Shan
Yongqiang Tang
Julie R. Graham
Sebastien Hazard
Leif W. Ellisen
Steven J. Isakoff
Nature Cancer, 2022, 3 : 1138 - 1138
[23] Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study
Miller, Robert S.
Mokiou, Stella
Taylor, Aliki
Jiang, Miao
Sun, Ping
McCutcheon, Susan
CANCER RESEARCH, 2021, 81 (04)
[24] Phase II study of olaparib plus durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
Drew, Y.
Kaufman, B.
Banerjee, S.
Lortholary, A.
Hong, S. H.
Park, Y. H.
Zimmermann, S.
Roxburgh, P.
Ferguson, M.
Alvarez, R. H.
Domchek, S.
Gresty, C.
Angell, H. K.
Ros, V. Rocher
Meyer, K.
Lanasa, M.
Herbolsheimer, P.
de Jonge, M.
ANNALS OF ONCOLOGY, 2019, 30
[25] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
Domchek, Susan M.
Robson, Mark
Im, Seock-Ah
Senkus, Elzbieta
Xu, Binghe
Masuda, Norikazu
Delaloge, Suzette
Li, Wei
Armstrong, Anne
Conte, Pierfranco
Bannister, Wendy
Goessl, Carsten
Runswick, Sarah
Goel, Saurabh
Tung, Nadine
CANCER RESEARCH, 2018, 78 (04)
[26] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Im, Seock-Ah
Xu, Binghe
Li, Wei
Robson, Mark
Ouyang, Quchang
Yeh, Dah-Cherng
Iwata, Hiroji
Park, Yeon Hee
Sohn, Joo Hyuk
Tseng, Ling-Ming
Goessl, Carsten
Wu, Wenting
Masuda, Norikazu
SCIENTIFIC REPORTS, 2020, 10 (01)
[27] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Seock-Ah Im
Binghe Xu
Wei Li
Mark Robson
Quchang Ouyang
Dah-Cherng Yeh
Hiroji Iwata
Yeon Hee Park
Joo Hyuk Sohn
Ling-Ming Tseng
Carsten Goessl
Wenting Wu
Norikazu Masuda
Scientific Reports, 10
[28] Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
Ales-Martinez, Jose E.
Balmana, Judith
Sanchez-Rovira, Pedro
Bofill, Francisco Javier Salvador
Garcia-Saenz, Jose Angel
Pimentel, Isabel
Murillo, Serafin Morales
Fernandez, Adela
Martinez, Ainhara Lahuerta
Ferrer, Neus
Zamora, Pilar
Bermejo, Begona
Diaz-Redondo, Tamara
Lopez-Ceballos, Maria Helena
Galan, Maria
Malfettone, Andrea
Calabuig, Laura
Sampayo-Cordero, Miguel
Perez-Garcia, Jose Manuel
Cortes, Javier
Llombart-Cussac, Antonio
CANCER RESEARCH, 2023, 83 (05)
[29] LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation
Gelmon, K. A.
Walker, G. P.
Fisher, G. V.
McCutcheon, S. C.
ANNALS OF ONCOLOGY, 2018, 29
[30] Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Banerjee, S.
Imbimbo, M.
Roxburgh, P.
Kim, J-W.
Kim, M. H.
Plummer, R.
Stemmer, S.
You, B.
Ferguson, M.
Penson, R. T.
O'Malley, D.
Meyer, K.
Gao, H.
Angell, H.
Nunes, A. Tablante
Domchek, S.
Drew, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S788 - S789

← 1 2 3 4 5 →